Advertisement

Reactions Weekly

, Volume 1736, Issue 1, pp 182–182 | Cite as

Sorafenib

Focal segmental glomerulosclerosis and thrombotic microangiopathy: case report
Case report
  • 14 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

A 64-year-old man developed focal segmental glomerulosclerosis (FSGS) and thrombotic microangiopathy (TMA) during treatment with sorafenib for recurrent hepatocellular carcinoma.

The man, who had hepatitis-C virus infection, hepatocellular carcinoma, mild proteinuria and mild chronic kidney disease (CKD), underwent orthotopic liver transplant (OLT) in August 2013. Post-OLT, he started receiving tacrolimus. He was suspected to have hepato-renal syndrome and contrast induced nephropathy. In the middle of November 2013, he was diagnosed with recurrent hepatocellular carcinoma and subsequently started receiving oral sorafenib [dosage not stated]. Just before initiation of sorafenib, his serum creatinine had decreased to a nadir. Prior to initiation of sorafenib, a urinalysis...

Reference

  1. Hanna RM, et al. Development of Focal Segmental Glomerulosclerosis and Thrombotic Microangiopathy in a Liver Transplant Patient on Sorafenib for Hepatocellular Carcinoma: A Case Report. Transplantation Proceedings 50: 4033-4037, No. 10, Dec 2018. Available from: URL: http://doi.org/10.1016/j.transproceed.2018.07.020 - USA

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations